Published in Mol Pharm on May 06, 2011
Promising Therapy Candidates for Liver Fibrosis. Front Physiol (2016) 0.85
Gli1 activation and protection against hepatic encephalopathy is suppressed by circulating transforming growth factor β1 in mice. J Hepatol (2014) 0.83
Developmental Status: Impact of Short-Term Ischemia on Follicular Survival of Whole Ovarian Transplantation in a Rabbit Model. PLoS One (2015) 0.78
Inhibition of smoothened decreases proliferation of synoviocytes in rheumatoid arthritis. Cell Mol Immunol (2015) 0.78
Protective effects of pretreatment with oleanolic acid in rats in the acute phase of hepatic ischemia-reperfusion injury: role of the PI3K/Akt pathway. Mediators Inflamm (2014) 0.76
Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem (1979) 41.65
Communicating with Hedgehogs. Nat Rev Mol Cell Biol (2005) 5.01
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med (1990) 4.72
Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol (2006) 3.05
Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol (1991) 2.67
Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation (1993) 2.62
The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant (2008) 2.48
Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J (1990) 2.41
The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut (2008) 2.26
Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology (2009) 2.25
Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab Invest (2007) 2.03
Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology (2003) 2.00
Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology (1997) 1.95
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis (2005) 1.91
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
GLI2 is expressed in normal human epidermis and BCC and induces GLI1 expression by binding to its promoter. J Invest Dermatol (2004) 1.76
Role of neutrophils in acute inflammatory liver injury. Liver Int (2006) 1.72
Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol (1998) 1.68
Interplays of Gli2 and Gli3 and their requirement in mediating Shh-dependent sclerotome induction. Development (2003) 1.68
The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology (1996) 1.61
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. Oncogene (2007) 1.53
Suppression of tumor necrosis factor-alpha production and neutrophil infiltration during ischemia-reperfusion injury of the liver after heat shock preconditioning. J Hepatol (2001) 1.50
Hedgehog signalling in cancer. Cell Mol Life Sci (2000) 1.44
Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol (2003) 1.40
The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol (2000) 1.31
Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol (2000) 1.29
Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol (2002) 1.25
Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl (2003) 1.19
Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology (2009) 1.17
Bile secretory function of intrahepatic biliary epithelium in the rat. Am J Physiol (1989) 1.15
Sub-lethal oxidative stress triggers the protective effects of ischemic preconditioning in the mouse liver. J Hepatol (2003) 1.13
Vertebrate mesendoderm induction and patterning. Curr Opin Genet Dev (2000) 1.12
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther (2010) 1.01
Hedgehog signal activation coordinates proliferation and differentiation of fetal liver progenitor cells. Exp Cell Res (2009) 1.00
Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr Opin Pharmacol (2004) 0.99
Obstructive jaundice impairs hepatic sinusoidal endothelial cell function and renders liver susceptible to hepatic ischemia/reperfusion. J Hepatol (2000) 0.95
Novel actions of aspirin and sodium salicylate: discordant effects on nitric oxide synthesis and induction of nitric oxide synthase mRNA in a murine macrophage cell line. J Leukoc Biol (1996) 0.92
Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17β-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology (2010) 0.92
Hedgehog signaling in biliary fibrosis. J Clin Invest (2008) 0.92
The marginal donor: a single-center experience in orthotopic liver transplantation. Transplant Proc (2006) 0.91
Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol Sin (2007) 0.90
Splanchnic ischemia and reperfusion injury is reduced by genetic or pharmacological inhibition of TNF-alpha. J Leukoc Biol (2007) 0.88
Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse. Gut (2006) 0.87
Inhibition of endogenous hedgehog signaling protects against acute liver injury after ischemia reperfusion. Pharm Res (2010) 0.84
The severity of cholestatic injury is modulated by the genetic background. Shock (2005) 0.82
Peroxynitrite attenuates hepatic ischemia-reperfusion injury. Am J Physiol Cell Physiol (2000) 0.80
Hepatic stellate cells reversibly express alpha-smooth muscle actin during acute hepatic ischemia. Transplant Proc (1997) 0.79
Selectin inhibition modulates NF-kappa B and AP-1 signaling after liver ischemia/reperfusion. J Invest Surg (2006) 0.79
Hepatocellular ultrastructure after ischemia/reperfusion injury in human orthotopic liver transplantation. J Gastrointest Surg (2004) 0.78
Systematic search for placental DNA-methylation markers on chromosome 21: toward a maternal plasma-based epigenetic test for fetal trisomy 21. Clin Chem (2008) 2.14
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA (2007) 1.46
Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev (2006) 1.45
Paternal genetic affinity between Western Austronesians and Daic populations. BMC Evol Biol (2008) 1.33
Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One (2012) 1.20
TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm (2009) 1.13
Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules (2002) 1.12
Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res (2011) 1.12
Mesenchymal stem cell-based therapy. Mol Pharm (2012) 1.09
Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res (2009) 1.07
RNAi for treating hepatitis B viral infection. Pharm Res (2007) 1.05
Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev (2010) 1.04
Enhanced hepatic uptake and bioactivity of type alpha1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther (2006) 1.02
Vascular endothelial growth factor gene delivery for revascularization in transplanted human islets. Pharm Res (2004) 1.01
Caspase-3 gene silencing for inhibiting apoptosis in insulinoma cells and human islets. Mol Pharm (2009) 1.00
Biodistribution and hepatic uptake of triplex-forming oligonucleotides against type alpha1(I) collagen gene promoter in normal and fibrotic rats. Mol Pharm (2005) 0.99
Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst (2007) 0.99
Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv (2010) 0.99
miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett (2012) 0.98
Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function. Pharm Res (2006) 0.97
Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem (2010) 0.97
Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J Control Release (2002) 0.94
Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model. Mol Ther (2013) 0.92
Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study. Liver Transpl (2009) 0.92
iNOS gene silencing prevents inflammatory cytokine-induced beta-cell apoptosis. Mol Pharm (2008) 0.91
Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets. Mol Pharm (2009) 0.91
Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer. Pharm Res (2012) 0.91
Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. Pharm Res (2012) 0.91
Hypoxia-specific gene expression for ischemic disease gene therapy. Adv Drug Deliv Rev (2009) 0.91
Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells. Biochemistry (2005) 0.91
Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. J Drug Target (2012) 0.90
Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Mol Pharm (2012) 0.90
Genetically modified mesenchymal stem cells for improved islet transplantation. Mol Pharm (2011) 0.88
Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules (2010) 0.88
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug Chem (2005) 0.87
Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials (2010) 0.87
Early postoperative hepatic sonography as a predictor of vascular and biliary complications in adult orthotopic liver transplant patients. AJR Am J Roentgenol (2005) 0.86
Structural and formulation factors influencing pyridinium lipid-based gene transfer. Bioconjug Chem (2008) 0.86
Receptor-mediated hepatic uptake of M6P-BSA-conjugated triplex-forming oligonucleotides in rats. Bioconjug Chem (2006) 0.86
Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation. Pharm Res (2008) 0.86
Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function. Mol Pharm (2007) 0.86
RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantation. J Gene Med (2011) 0.85
Sequence-specific triple helix formation with genomic DNA. Biochemistry (2007) 0.85
Delivery and targeting of miRNAs for treating liver fibrosis. Pharm Res (2014) 0.85
Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjug Chem (2007) 0.84
RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev (2010) 0.84
Inhibition of endogenous hedgehog signaling protects against acute liver injury after ischemia reperfusion. Pharm Res (2010) 0.84
Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma. Bioconjug Chem (2013) 0.83
Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation (2006) 0.83
Effect of iNOS and NF-kappaB gene silencing on beta-cell survival and function. J Drug Target (2007) 0.83
Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Expert Opin Drug Deliv (2012) 0.83
HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells. Bioconjug Chem (2009) 0.83
Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation. Pharm Res (2011) 0.83
XIAP gene expression protects β-cells and human islets from apoptotic cell death. Mol Pharm (2010) 0.83
siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target (2008) 0.83
Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. J Control Release (2010) 0.83
Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival. Clin Transpl (2008) 0.82
Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. Mol Pharm (2014) 0.82
Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting. Exp Clin Transplant (2013) 0.81
Characterizing dietary intake and physical activity affecting weight gain in kidney transplant recipients. Prog Transplant (2012) 0.81
GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis. Pharm Res (2011) 0.81
Targeted TFO delivery to hepatic stellate cells. J Control Release (2011) 0.80
Mesenchymal stem cell-based therapy for type 1 diabetes. Discov Med (2014) 0.80
Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Deliv Transl Res (2011) 0.80
MicroRNAs and drug resistance in prostate cancers. Mol Pharm (2014) 0.80
Triplex forming oligonucleotides against type α1(I) collagen attenuates liver fibrosis induced by bile duct ligation. Biochem Pharmacol (2010) 0.79
Miller fisher variant of guillain-barre syndrome requiring a cardiac pacemaker in a patient on tacrolimus after liver transplantation. Ann Pharmacother (2005) 0.79
Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis. Pharm Res (2013) 0.79
Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for rapamycin delivery: in vitro characterization and biodistribution. J Pharm Sci (2011) 0.79
siRNA delivery and targeting. Mol Pharm (2009) 0.79
Role of nanomedicines in cell-based therapeutics. Nanomedicine (Lond) (2008) 0.78
Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent. Pharm Res (2012) 0.78
Genetically modified human bone marrow derived mesenchymal stem cells for improving the outcome of human islet transplantation. PLoS One (2013) 0.77
Magnetic resonance imaging in pancreas transplantation. Top Magn Reson Imaging (2009) 0.77
Bipartite vectors for co-expression of a growth factor cDNA and short hairpin RNA against an apoptotic gene. J Gene Med (2009) 0.77
Biological and therapeutic applications of small RNAs. Pharm Res (2011) 0.77
Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl (2003) 0.77
Recidivism in Liver Transplant Recipients With Alcoholic Liver Disease: Analysis of Demographic, Psychosocial, and Histology Features. Exp Clin Transplant (2015) 0.77
Innovative medical management with resection for successful treatment of pulmonary mucormycosis despite diagnostic delay. J La State Med Soc (2002) 0.77
LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer. Pharm Res (2014) 0.77
Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients. Transplantation (2015) 0.76
Liver transplantation at the University of Tennessee Health Science Center in Memphis, Tennessee: the current era 2006-2012. Clin Transpl (2012) 0.76
Liver transplant using donors after cardiac death: a single-center approach providing outcomes comparable to donation after brain death. Exp Clin Transplant (2013) 0.76
Liver transplantation for hepatocellular carcinoma: the ochsner experience. Ochsner J (2002) 0.76
Therapeutic cell delivery for in situ regenerative medicine. Adv Drug Deliv Rev (2010) 0.76
The use of HBsAg-positive organ donors: far more than meets the eye? Liver Transpl (2005) 0.76